01—Abstract
Summary
Summary of the 10-K filed February 23, 2009. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported a net loss of $521.8 milliona for fiscal 2008 (fiscal year ended December 27, 2008), compared with net income of $154.4 million in 2007.
The result was driven by a $700.0 millionb goodwill impairment charge related to the Preclinical Services (PCS) business, which produced an operating loss of $449.8 million for the company. Excluding that charge, the filing shows net sales growth: total net sales were $1,343.5 million, up 9.2% from $1,230.6 million in 2007. Research Models and Services (RMS) net sales rose 14.3% to $659.9 million, while PCS net sales rose 4.6% to $683.6 million, though demand decelerated in the second half of 2008 as pharmaceutical and biotechnology customers restructured and reprioritized pipelines.
Management's outlook for 2009 is cautious. The company expects softer demand, particularly for preclinical services, at least until mid-year. It has taken cost actions including a hiring freeze, salary freeze, and a 3% headcount reduction, with a one-time charge of approximately $9.0 millionc, and is pursuing strategic alternatives for its Scotland Phase I clinical operation.
Capital expenditures were $197.1 milliond in 2008 and are planned at $100 million to $120 million for 2009, and the Ohio expansion has been delayed until 2010. Total debt was $575.8 million at year-end, and shareholders' equity fell to $1,199.0 million from $1,860.5 million. For investors, the key points are the impairment's effect on reported earnings, the slowdown in preclinical demand, and the company's balance sheet and cash position.
Cash and cash equivalents were $243.6 million, and operating cash flow was $279.5 million. The company repurchased $115.1 million of treasury stock during 2008 and expects to repatriate approximately $90.0 million of non-U.S. earnings in the first quarter of 2009.
02—Key points
Key Highlights
- Net loss of $521.8 million in 2008, versus net income of $154.4 million in 2007, driven by a $700.0 million goodwill impairment in the PCS segment
- Net sales of $1,343.5 million, up 9.2% from $1,230.6 million; RMS sales rose 14.3% to $659.9 million and PCS sales rose 4.6% to $683.6 million
- Demand decelerated in the second half of 2008 as pharmaceutical and biotechnology clients restructured and reprioritized pipelines; management expects softer preclinical demand at least until mid-2009
- 2009 cost actions include a hiring freeze, salary freeze, 3% headcount reduction, and a one-time charge of approximately $9.0 million, with expected savings of approximately $20.0 million in 2009
- Capital expenditures of $197.1 million in 2008, with 2009 plans of $100 million to $120 million; Ohio facility expansion delayed until 2010
- Total debt of $575.8 million at year-end, including $350.0 million of 2.25% convertible senior notes due 2013; cash and cash equivalents of $243.6 million
- Operating cash flow of $279.5 million in 2008; $115.1 million spent on treasury stock purchases during the year
03—One dollar
Follow one dollar
For each $1.00 of revenue in FY2008, Charles River Laboratories International lost $0.40.
- Revenue$1.30B100.0%
- Cost of revenue−$252.9M19.5%
- Gross profit$1.04B80.5%
- Operating costs−$1.49B115.4%
- Operating income−$451.8M34.9%
- Interest, other & tax−$72.7M5.6%
- Net income−$524.5M40.5%
04—Financials
Financial Highlights
Figures from 10-KFY2008filed February 23, 2009Financial Statements
05—Questions
Frequently Asked Questions
What caused the large net loss in 2008?
The net loss of $521.8 million was primarily caused by a $700.0 million goodwill impairment charge on the Preclinical Services business. The impairment followed a deterioration in economic conditions in late 2008, weaker business performance and outlook, and a decrease in market capitalization, which triggered a second goodwill impairment test as of December 27, 2008.
How did the company's revenue perform in 2008?
Total net sales were $1,343.5 million, an increase of 9.2% from $1,230.6 million in 2007. Research Models and Services grew 14.3% and Preclinical Services grew 4.6%, although demand for services slowed during the second half of the year.
What is management's outlook for 2009?
The filing expects softer market demand, particularly for preclinical services, continuing at least until mid-year 2009. Management is responding with cost reductions, has delayed the Ohio expansion until 2010, and plans capital expenditures of $100 million to $120 million. The company also expects to repatriate approximately $90.0 million of non-U.S. earnings in the first quarter of 2009.
How is the company's balance sheet positioned?
At December 27, 2008, the company had total assets of $2,159.9 million, total debt of $576.1 million, and shareholders' equity of $1,199.0 million, down from $1,860.5 million a year earlier. Cash and cash equivalents were $243.6 million. The company stated it was compliant with all financial covenants under its credit agreements.
Does the company pay dividends or repurchase shares?
The company has not declared or paid cash dividends in the past two years and does not intend to pay them in the foreseeable future. It repurchased 2,159,908 shares for $109.3 million under its Rule 10b5-1 plans during 2008, and about $187.1 million remained authorized under its $600.0 million repurchase program as of December 27, 2008.
06—Continue